To study the outcomes of Multiple Myeloma patients who developed a relapse after transplant
Not Applicable
- Conditions
- Health Condition 1: C900- Multiple myeloma
- Registration Number
- CTRI/2024/04/066154
- Lead Sponsor
- Advanced Centre for Training, Research and Education in Cancer
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients of Multiple myeloma who have undergone ASCT
-Patients who have relapsed post ASCT
Exclusion Criteria
-Other plasma cell dyscrasias who undergo ASCT (like AL amyloidosis, POEMS syndrome etc)
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method - Response rates with first salvage regimen in Multiple myeloma patients who relapse post ASCT <br/ ><br>- PFS-2 rates with different salvage regimens in Multiple myeloma <br/ ><br>Timepoint: 1 year
- Secondary Outcome Measures
Name Time Method -Incidence of relapse or progression post ASCT <br/ ><br>-Time to relapse or progression post ASCT <br/ ><br>-PFS-1 post ASCT in standard versus high-risk Multiple myeloma <br/ ><br>-Overall Survival in Multiple Myeloma patients who relapse post ASCT <br/ ><br>-Median time to start of first salvage post ASCT <br/ ><br>-Median number of relapses or progression post ASCT <br/ ><br>-Median number of salvage therapies given post ASCTTimepoint: 1 year